Immunodiagnostic Systems Share Discussion Threads

[silverfern] 01/4/2008 07:46

...and here is the trading update no doubt to reassure the market. We knew turnover would move up, and it has and that costs associated with the new businesses would hold back profits, but that was forecast and they have met broker's expectations. They seem on target with this strategically sound model

Reminder: The company broker's note dated 10th December 2007 projects EPS of 9.8p for 2007/8, 16.2p for 2008/9 and 26.2p for 2009/10 which my calcs equate to P/Es of 17.8, 10.8 and 6.6 based on the share price of 175p

[the count] 31/3/2008 22:58

THE COUNT--->SILVERFERN

There is no reason except for a terrible market in the smaller caps, and even worse in the most illiquid of those.

I checked recently with the company and the busniness model is intact. Over 3 - 4 years, this is a 5+ bagger.

Also expect newsflow very soon. Hopefully the recent rapid fall will spur them into some action.

I picked up a few in the recent falls but didn't have enough to buy more in the last couple of trading days.

This will turn out to be a very good medium term investment for the patient among you, I'm sure.

Regards,

THE COUNT!

[silverfern] 31/3/2008 22:41

Looks like we'll be testing that theory matey. Any one out there know why this has fallen at this time?

[myoldmate] 06/2/2008 21:57

Chartwise should £2 be breached then, to my eye, £1.70 provides the next real resistance.

[yellowdog] 06/2/2008 19:51

i sold out at 230ish and have been waiting for the price to fall so i can buy in again.if it falls below 200p am buying.

[myoldmate] 06/2/2008 17:53

Tempting isn't it, but you're a better man than I if you can tell if this is as low as it'll go.

[geologic] 06/2/2008 15:39

thanks.good time to buy then?

[the count] 06/2/2008 15:37

THE COUNT--->GEOLOGIC

Very low liquidity...a few sporadic sales in a lousy market and Bob's yer uncle.

Regards,

THE COUNT!

[geologic] 06/2/2008 15:36

anyone know why the share price is falling?time to buy?

[alftupper] 28/1/2008 21:47

Good article in Investors Chronicle on IDH

[myoldmate] 27/1/2008 18:27

Obviously nothing as it was was posted in October as a follow up to his earlier comments, just thought you might like to read it.

Has anyone got a whiff off what Oriel had to say in the brokers note they released?

[silverfern] 27/1/2008 18:14

I agree, well written but what's new?

[myoldmate] 27/1/2008 17:04

A further summary from Colin over on TMF. Clear, concise and as well written as ever.

[alftupper] 14/1/2008 05:46

A takeout at £3 a share would be significantly undervaluing this and I just cannot see it happening in any short timescale - two years out possibly.

[myoldmate] 11/1/2008 18:17

We got a mention in the IC this week as one of AIMs top 45 shares.

The article finished with the prediction of a takeover at >£3.

[sheeneqa] 11/1/2008 09:44

Immunodiagnostic Systems says launches assay for bone formation biomarker




LONDON (Thomson Financial) - Immunodiagnostic Systems Holdings PLC said it
has launched the world's first assay for a biomarker for bone formation, which
it expects to help in the assessment of new osteoporosis drug candidates in
pre-clinical studies and cancer research.
The immunoassay kits maker said the assay to determine the Rat/Mouse Type I
procollagen amino-terminal propeptide (PINP) biomarker in serum is of particular
value in monitoring the efficacy of expensive bone therapies.
The company expects the availability of this assay could lead to new
insights and breakthroughs in the bone disease and cancer markets.
It added that the new product has already been well received in pre-release
evaluations.

Immunodiagnostic Sys New Rat/Mouse PINP Assay




RNS Number:5428L
Immunodiagnostic Systems Hldgs PLC
11 January 2008



Immunodiagnostic Systems Holdings plc
("IDS" or "The Group")


Launch of unique rat/mouse PINP assay for pharmaceutical,
clinical and academic research organisations.



Immunodiagnostic Systems Holdings plc ("IDS"), a leading producer of diagnostic
testing kits for the clinical and research markets, announces the launch of the
world's first assay for Rat/Mouse Type I procollagen amino-terminal propeptide
(PINP), a biomarker for bone formation.

Determining the level of PINP in serum is of particular value in monitoring the
efficacy of expensive bone therapies. Previously it was not possible to
quantitate PINP in rats and mice, which are the main subjects used by the
pharmaceutical industry, and so this assay will greatly aid in the assessment of
new osteoporosis drug candidates in pre-clinical studies and in fundamental
cancer research by pharmaceutical, biomedical and academic research
organisations.

This new product has already been well received in pre-release evaluations.
Customers particularly value the sensitivity and specificity of the method. A
very small sample is required and it has total specificity for rodent PINP
(human PINP is not recognised).

The PINP biomarker product can now be used with other highly complementary
assays already in the IDS range for research into bone disease and cancer. The
availability of this assay could potentially give new insights and breakthroughs
in the bone disease and cancer markets.

IDS designs, develops, manufactures and markets a wide range of immunoassay
kits, and is particularly active in the field of Bone & Mineral metabolism with
a growing presence in the field of Cancer Research.


Dr Roger Duggan, Managing Director of IDS, said:

"This unique product fills a longstanding gap in the armoury of researchers
seeking to understand the mechanisms of bone formation, and will aid in the
identification of modulators of the growth of bone and of bone metastases. The
launch of rat/mouse PINP also restates the commitment of IDS to the field of
Bone & Skeletal biology and our ability to meet the needs of 'big Pharma'. On a
different level, the launch is particularly pleasing for IDS, as it represents
the first successful launch of a new analyte developed by a Finnish consultant,
in association with our subsidiary, SBA Sciences, acquired in 2005."

[the count] 10/1/2008 13:26

THE COUNT--->ALL


Daniel Stewart have initiated coverage of IDH today with a 'buy' rating and set a target price of 319p.

Nice to see that it is slowly being noticed.

Regards,

THE COUNT!

[myoldmate] 08/1/2008 20:07

Update from the Armshare summary.

The interim results to September 2007 showed sales of £6.8 million (2006: £4.5 million), pre-tax profit of £1.3 million (2006: £742,000) and adjusted EPS of 5.6p (2006; 4.2p). The company reported that like-for-like sales grew 17%; re the 3x3 instrument, it has been tested by potential customers in non-clinical environments, the design should be frozen during January 2008, first sales will be into the biochemistry market and these are scheduled to be followed in H2 2008 by sales for immunoassays, once the creation of a menu of bone panel tests has been completed - the board believes that this will be the most comprehensive automated bone panel in the world; the first automated test was developed, on time, under contract to a major pharmaceutical company; period end net debt was £7.9 million; in line with the historical trend, higher sales are expected in H2 than H1.

Research Standing.

The attractions of diagnostics are the recurring revenue streams enjoyed and the leverage obtained from new treatments being developed - this is particularly true in the field of bones, where aging populations are increasing the universe with bone problems and significant resource is being devoted to developing new treatments/bone growth promotants - patient outcomes benefit from both earlier diagnosis and also monitoring during treatment.

The company broker's note dated 10th December 2007 projects EPS of 9.8p for 2007/8, 16.2p for 2008/9 and 26.2p for 2009/10 representing P/Es of 23.2, 14.0 and 8.7 based on the share price of 227.5p at 10th December.

Despite multiplying over 4.5x in the 2.5 years since the IPO launch at 51p, the share price still looks reasonable value having regard to the rate of EPS growth, the business activity/model and the vision for IDS within the bone & skeletal biomarker market.

COMPANY MEETINGS

i) With CEO, Dr Roger Duggan, and FD, Paul Hailes, on 10th December 2007

Key points to emerge were:

a) 3x3 automated analyser (see final results to March 2007)

The reasons for the acquisition of this instrument being expected to provide a step change to the scale of the IDS business are:

- Nichols Institute which was funding the development of the instrument until its demise was selling c.$80 million of automated bone assays pa based on 6 products. Since the demise of Nichols, many of its customers have had to revert to manual assays. The only other significant competitor sells an automated analyser which is 12 years old.

- IDS has the same 6 products which Nichols was selling. In addition, Nordic Bioscience Diagnostics (see July 2007) brings another 6 products, which combined with the IDS products provides IDS with a unique portfolio of bone assays.

b) Nordic Bioscience Diagnostics (NBD - see July 2007)

NBD is scheduled to become a direct sales entity by March 2008 - this is expected to improve group profitability by c.£500,000 pa. In addition, NBD's production is scheduled to be moved to Boldon by May 2008, which is expected to improve profitability by c.£350,000 pa.

[myoldmate] 08/1/2008 19:04

And the ASD connection continues with us now having Christopher Cookson as operations director.

[george19] 08/1/2008 14:30

That would be nice Count. The SP, in my opinion, has held up quite well in view of the recent market turmoil. I took profits a few months back but still hold a few. A 3 - 5 bagger would be nice but I'll settle for a double over the next year. :o)

[felix99] 08/1/2008 14:06

key is new machines COunt - if 3 x 3 is launched without a hitcha and it all goes swimmingly I agree. But I'll wager there is a hicupp or two along the way.

These things are not easy to place as no one will buy them until they are proven clinically and reliably etc etc. No -one wants to be first to have one so its a chicken and egg jobby.

[the count] 08/1/2008 10:04

THE COUNT--->GEORGE19

We are also due a research note soon that should put a bit of meat to the bones and give us some idea of what to expect.

I think over the next 3 years, we may have a potential 3 - 5 bagger in the making assuminmg their aquisitions are bedded in wihtout any great hitch.

Regards,

THE COUNT!

[george19] 06/1/2008 19:33

COUNT - Thanks for the info.

[myoldmate] 06/1/2008 17:54

Yep still here waiting patiently.

Personally I don't expect much to happen in the near future. IDH are still in the the early stages of their 'transformation'.

At the time of the results they stated that there is a 12 month window for the 3x3 to receive regulatory approval in the USA and Japan, which if successful, and is there any reason it wont be?, should clear the way for our products to be utilised virtually across half the world.

Having said that we are as susceptible to outside market forces as any other company and should the market continue to decline then we will be caught in the slipstream as well.

For the record I am a long term holder and will remain so through thick and thin as I believe that the companys strategy is right and will eventually be amply rewarded.